Obstructive Sleep Apnea Syndrome Is Less Frequent in Patients With 
Well-Controlled Acromegaly Treated With Somatostatin Analogues, Pegvisomant or 
in Combination

Herrmann, Burkhard L.; Stalla, Guenter K.; Laubner, Katharina; Bidlingmaier, Martin; Fuehrer-Sakel, Dagmar

doi:10.14740/jem455w

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Obstructive Sleep Apnea Syndrome Is Less Frequent in Patients With Well-Controlled Acromegaly Treated With Somatostatin Analogues, Pegvisomant or in Combination

MPS-Authors

/persons/resource/persons80539

Stalla, Guenter K.
RG Clinical Neuroendocrinology, Clinical Research, Max Planck Institute of Psychiatry, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

455-2844-2-PB.pdf
(Publisher version), 372KB

Supplementary Material (public)

There is no public supplementary material available

Citation

Herrmann, B. L., Stalla, G. K., Laubner, K., Bidlingmaier, M., & Fuehrer-Sakel, D. (2017). Obstructive Sleep Apnea Syndrome Is Less Frequent in Patients With Well-Controlled Acromegaly Treated With Somatostatin Analogues, Pegvisomant or in Combination. JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 7(5), 141-145. doi:10.14740/jem455w.

Cite as: https://hdl.handle.net/21.11116/0000-0001-8830-F

Abstract

Background: Obstructive sleep apnea (OSA) often occurs in patients with active acromegaly and improves after treatment. Less is known about the development of OSA in patients after a longer period of control treated with somatostatin analogues (SSA) and pegvisomant. Methods: Seventy-nine patients (12 females, 17 males; age 49 +/- 14 years; body mass index 29.9 +/- 5.4 kg/m(2); IGF-1 184 +/- 73 mu g/L; disease duration 13 +/- 8 years (mean +/- standard deviation)) with wellcontrolled acromegaly treated with SSA (38%), pegvisomant (38%) or in combination (24%) who underwent ambulatory polygraphy were included in a prospective multicenter cross-sectional study. Results: Fourteen percent had OSA (range of apnea-hypopnea index (AHI) 5 -15). Patients with OSA (AHI >= 5 vs. < 5) had a longer disease duration (16 +/- 1 vs. 12 +/- 8 years; P = 0.01) and were older (61 +/- 9 vs. 47 +/- 13 years; P = 0.037). The AHI of all patients correlated with age (P = 0.01; r = 0.44). No differences were seen in terms of BMI and Epworth sleepiness scale score. Previous transsphenoidal surgery and radiation had no impact of the detection of OSA. The duration of well-controlled acromegaly was 7 +/- 3 years. Conclusion: OSA in patients with well-controlled acromegaly treated with SSA, pegvisomant or in combination is less frequent (14%) than previously described. Early treatment to reduce the active disease period should be aimed to prevent OSA.